1 / 11

Case study

Case study. Wilson Disease Miranda Durkie 2009. WD introduction. Autosomal recessive disorder of Cu metabolism Incidence 1 in 30,000 Presentation hepatic (usually childhood) or neurological (later age-of-onset) Treatment by chelating agents very effective if given early

baird
Télécharger la présentation

Case study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case study Wilson Disease Miranda Durkie 2009

  2. WD introduction • Autosomal recessive disorder of Cu metabolism • Incidence 1 in 30,000 • Presentation hepatic (usually childhood) or neurological (later age-of-onset) • Treatment by chelating agents very effective if given early • Mutations spread throughout all 21 exons but mutation hot-spots recognised

  3. SDGS testing strategy • Analysis by DNA sequencing of 7 out of the 21 exons detects >80% of mutations found in UK population = Stage 1 screen • Rest of gene = Stage 2 screen • Unless specifically says otherwise do St1 only & report results. • Second referral required for St2 analysis

  4. Case Study • Affected female, CT, aged 26, fulminant liver failure requiring liver transplant • St1 sequencing found 2 putative mutations p.Ile381Ser + p.Arg723GlufsX32 • p.Ile381Ser novel missense; 5/5 in silico tools predict pathogenic • Reported as “consistent with a diagnosis of Wilson disease” but without functional studies we cannot be certain of significance of p.Ile381Ser

  5. Case study cont.1 • Whilst issuing report for CT, samples rec’d from her 2 daughters TM & MM • Referral letter says “Penicillamine challenge info is ambiguous for TM. Whilst this would not be sufficient to make a diagnosis in a symptomatic patient, in a child of 6 years without symptoms we would like to exclude condition genetically” • Asked for father’s sample to test – no reply • After 4 months delay rec’d another letter asking for results for TM & MM • Phone call to clinician

  6. Case study cont.2 • Father not available for testing • Unhappy that results were delayed • Did full St1 & St2 screen on the 2 daughters • MM inherited p.Arg723GlufsX32 mutation • TM inherited p.Ile381Ser putative mutation • Found additional missense change in TM p.Ile1184Thr; highly conserved base; 4/5 in silico tools predict pathogenic (not Align GVGD)

  7. Case study cont.3 • Difficult to interpret as genotype not seen in affected individual • Report said “as p.Ile381Ser & p.Ile1184Thr putative mutations affect highly conserved bases they are likely to be pathogenic. TM is therefore at risk of developing symptoms of WD” • Case discussed with Consultant Paediatric Hepatologist • Decided to do liver biopsy • Liver biopsy showed levels of Cu in normal range • TM started on zinc treatment

  8. Case study cont.4 • Routine family studies showed that grandmother also had same 2 missense changes as TM • Tested affected mother and she also had p.Ile1184Thr putative mutation therefore she has 3 mutations. • Reported to clinicians that p.Ile381Ser & p.Ile1184Thr in cis therefore TM unlikely to be affected • Literature search showed previously reported once in WD in isolated area with very high incidence and founder effect [1]

  9. Changes to report templates • Now have also found 2 more cases with 3 mutations • Discussed at WD best practice meeting and other labs reported similar findings but not published • Now reports all state “in light of rare reports[1],[2] of 2 putative mutations occurring on the same ATP7B allele we strongly recommend that xxxxx’s parents or other family members are tested to confirm the observed genotype” • WD EMQN has highlighted this in previous 3 years reports

  10. References • [1] Dedousiss GVZ et al (2005) Ann Hum Genet 69: 268-274 • [2] Data from this laboratory & personal communications from EMQN WD best practice meeting, June 2007.

  11. Topics for discussion • Full vs partial gene screening • Common or rare phenomena? • Confirmation of genotype in autosomal recessive disorders • Opinion of some clinicians that genetics is conclusive

More Related